2015
Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, Szymonifka J, Januzzi JL. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal Of Cardiovascular Translational Research 2015, 8: 164-172. PMID: 25777344, DOI: 10.1007/s12265-015-9618-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersChi-Square DistributionChronic DiseaseDisease ProgressionFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardiumNatriuretic Peptide, BrainNecrosisOdds RatioPeptide FragmentsPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsSystoleTime FactorsTroponin IVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLV systolic dysfunctionChronic heart failureHeart failureLV remodelingSerial measurementsHigh-risk clinical featuresLower CV event ratesCV event ratesDeleterious LV remodelingIndependent risk informationPoor cardiovascular outcomesPoor CV outcomesProgressive LV remodelingSensitive cardiac troponinMajority of patientsSignificant myocardial necrosisSensitive troponin assaysPg/mLCV outcomesHsTnI concentrationsCardiovascular eventsCardiovascular outcomesSystolic dysfunctionAdverse remodelingClinical features
2014
Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study
Gandhi PU, Szymonifka J, Motiwala SR, Belcher AM, Januzzi JL, Gaggin HK. Characterization and Prediction of Adverse Events From Intensive Chronic Heart Failure Management and Effect on Quality of Life: Results From the Pro-B-Type Natriuretic Peptide Outpatient-Tailored Chronic Heart Failure Therapy (PROTECT) Study. Journal Of Cardiac Failure 2014, 21: 9-15. PMID: 25463415, DOI: 10.1016/j.cardfail.2014.10.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersCardiovascular AgentsChronic DiseaseDisease ManagementDizzinessFemaleHeart FailureHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsProspective StudiesQuality of LifeRenal InsufficiencySurveys and QuestionnairesTreatment OutcomeConceptsTreatment-related serious adverse eventsSerious adverse eventsQuality of lifeAdverse eventsRisk scoreN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideChronic heart failure managementHeart Failure Questionnaire scoreWorse QOLAcute renal failureFirst cardiovascular eventHeart failure managementHeart failure therapyWorse functional classHighest-risk quartileCare armHF careHF managementSystolic HFCardiovascular eventsNT-proBNPReverse remodelingFailure therapyRenal failure